Adjuvant therapies, including chemotherapy, radiotherapy, hormonal agents and passive (antibody‐based) immunotherapy directed against human epidermal growth factor receptor 2 (HER2), reduce the rate of late metastasis and prolong survival in women with high‐risk breast cancer. This evidence concerns the gene ERBB2 and breast cancer.